Deprescribing proton pump inhibitors Evidence-based clinical practice guideline

被引:4
|
作者
Farrell, Barbara [1 ,2 ,3 ]
Pottie, Kevin [4 ,5 ,6 ]
Thompson, Wade [5 ]
Boghossian, Taline [7 ]
Pizzola, Lisa [6 ]
Rashid, Farah Joy [7 ]
Rojas-Fernandez, Carlos [8 ,9 ]
Walsh, Kate [10 ]
Welch, Vivian [5 ,11 ]
Moayyedi, Paul [12 ]
机构
[1] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[2] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[3] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Bruyere Res Inst, Ottawa, ON, Canada
[7] Ottawa Hosp, Dept Pharm, Ottawa, ON, Canada
[8] Univ Waterloo, Geriatr Pharmacotherapy, Schlegel UW Res Inst Ageing, Waterloo, ON, Canada
[9] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[10] Toronto Cent Community Care Access Ctr, Toronto, ON, Canada
[11] Bruyere Res Inst, Methods Ctr, Ottawa, ON, Canada
[12] McMaster Univ, Div Gastroenterol, Hamilton, ON, Canada
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; PANTOPRAZOLE; 20; MG; MAINTENANCE TREATMENT; LONG-TERM; ON-DEMAND; CONTROLLED TRIAL; PRIMARY-CARE; THERAPY; ESOPHAGITIS; MANAGEMENT;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing trials and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline. Recommendations This guideline recommends deprescribing PPIs (reducing dose, stopping, or using "on-demand" dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers. Conclusion This guideline provides practical recommendations for making decisions about when and how to reduce the dose of or stop PPIs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.
引用
收藏
页码:354 / 364
页数:11
相关论文
共 50 条
  • [11] Deprescribing Proton Pump Inhibitors
    Kurlander, Jacob E.
    Gonzalez, Juan J.
    Saini, Sameer D.
    JAMA INTERNAL MEDICINE, 2020, 180 (12) : 1711 - 1712
  • [12] Deprescribing strategies for proton pump inhibitors
    Young, Julia
    Fuller, Jordan A.
    Guidry, Corey M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2024, 37 (11): : 51 - 51
  • [13] Deprescribing Proton Pump Inhibitors Reply
    McDonald, Emily G.
    Lee, Todd C.
    JAMA INTERNAL MEDICINE, 2020, 180 (12) : 1712 - 1712
  • [14] Evidence-based Clinical Practice Guideline for CKD 2013
    Clinical and Experimental Nephrology, 2014, 18 : 346 - 423
  • [15] Evidence-based Clinical Practice Guideline for CKD 2013
    Japanese Society of Nephrology
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (03) : 346 - 423
  • [16] Proton pump inhibitors and their drug interactions: an evidence-based approach
    Gerson, LB
    Triadafilopoulos, G
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (05) : 611 - 616
  • [17] Proton pump inhibitors in cirrhosis:Tradition or evidence based practice?
    Francesca Lodato
    Francesco Azzaroli
    Maria Di Girolamo
    Valentina Feletti
    Paolo Cecinato
    Andrea Lisotti
    Davide Festi
    Enrico Roda
    Giuseppe Mazzella
    World Journal of Gastroenterology, 2008, (19) : 2980 - 2985
  • [18] Proton pump inhibitors in cirrhosis: Tradition or evidence based practice?
    Lodato, Francesca
    Azzaroli, Francesco
    Di Girolamo, Maria
    Feletti, Valentina
    Cecinato, Paolo
    Lisotti, Andrea
    Festi, Davide
    Roda, Enrico
    Mazzella, Giuseppe
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (19) : 2980 - 2985
  • [19] An Emulated Clinical Trial of Deprescribing Proton Pump Inhibitors in Patients With Cirrhosis
    Tapper, Elliot
    Zhao, Zhe
    Parikh, Neehar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (01): : 203 - 205
  • [20] Problems Associated with Deprescribing of Proton Pump Inhibitors
    Helgadottir, Holmfridur
    Bjornsson, Einar S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)